Transitions of care: Assessment of adherence to long-acting injectable antipsychotic treatment following discharge from inpatient psychiatry.

The mental health clinician Pub Date : 2025-02-03 eCollection Date: 2025-02-01 DOI:10.9740/mhc.2025.02.009
Charnae Ross, Katie S Adams, Ericka L Crouse
{"title":"Transitions of care: Assessment of adherence to long-acting injectable antipsychotic treatment following discharge from inpatient psychiatry.","authors":"Charnae Ross, Katie S Adams, Ericka L Crouse","doi":"10.9740/mhc.2025.02.009","DOIUrl":null,"url":null,"abstract":"<p><p><b>Introduction:</b> Long-acting injectable antipsychotics (LAI-APs) are used in patients with chronic psychiatric disorders as a strategy to manage oral medication nonadherence. Inpatient LAI-AP administration may assist with transition to the outpatient setting. The study objective was to characterize receipt of the next LAI-AP injection as planned in the outpatient setting following administration during inpatient psychiatric hospitalization. <b>Methods:</b> Patients 18 years and older were eligible for inclusion if they received an LAI-AP while inpatient and provided consent to monitor their 90-day follow-up. The primary outcome determined the percentage of patients who received the same LAI-AP administered during their inpatient psychiatric admission at their initial visit post discharge. The secondary outcomes compared appropriate documentation of the LAI-AP follow-up plan, oral overlap, and early psychiatric rehospitalization rates. <b>Results:</b> Fifty-one patients were included. Twenty-nine patients (56.9%) followed up within the outpatient setting after discharge and received their next scheduled LAI-AP as planned. Twenty-two patients (43.1%) did not receive an LAI-AP injection following discharge, 15 of whom did not attend their initial follow-up appointment. Thirty-nine patients (76.5%) were newly initiated on LAI-AP therapy, 19 of whom received their next follow-up injection. <b>Discussion:</b> More than 40% of patients who received an LAI-AP inpatient did not follow up in the outpatient setting despite appropriate discharge planning. Patients more likely to receive follow-up LAI-AP were older, received a maintenance injection while inpatient, and had a scheduled follow-up appointment. Prior to inpatient administration of LAI-AP, multiple factors should be considered, including outpatient adherence, access, feasibility of outpatient continuation, and transition of care plan.</p>","PeriodicalId":101313,"journal":{"name":"The mental health clinician","volume":"15 1","pages":"9-16"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11835369/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The mental health clinician","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.9740/mhc.2025.02.009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Long-acting injectable antipsychotics (LAI-APs) are used in patients with chronic psychiatric disorders as a strategy to manage oral medication nonadherence. Inpatient LAI-AP administration may assist with transition to the outpatient setting. The study objective was to characterize receipt of the next LAI-AP injection as planned in the outpatient setting following administration during inpatient psychiatric hospitalization. Methods: Patients 18 years and older were eligible for inclusion if they received an LAI-AP while inpatient and provided consent to monitor their 90-day follow-up. The primary outcome determined the percentage of patients who received the same LAI-AP administered during their inpatient psychiatric admission at their initial visit post discharge. The secondary outcomes compared appropriate documentation of the LAI-AP follow-up plan, oral overlap, and early psychiatric rehospitalization rates. Results: Fifty-one patients were included. Twenty-nine patients (56.9%) followed up within the outpatient setting after discharge and received their next scheduled LAI-AP as planned. Twenty-two patients (43.1%) did not receive an LAI-AP injection following discharge, 15 of whom did not attend their initial follow-up appointment. Thirty-nine patients (76.5%) were newly initiated on LAI-AP therapy, 19 of whom received their next follow-up injection. Discussion: More than 40% of patients who received an LAI-AP inpatient did not follow up in the outpatient setting despite appropriate discharge planning. Patients more likely to receive follow-up LAI-AP were older, received a maintenance injection while inpatient, and had a scheduled follow-up appointment. Prior to inpatient administration of LAI-AP, multiple factors should be considered, including outpatient adherence, access, feasibility of outpatient continuation, and transition of care plan.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
护理的转变:精神病住院出院后长期注射抗精神病药物治疗依从性的评估。
长效注射抗精神病药物(LAI-APs)用于慢性精神疾病患者,作为管理口服药物依从性的策略。住院患者的LAI-AP管理可能有助于过渡到门诊设置。该研究的目的是描述在精神科住院期间给药后,在门诊环境中按计划接受下一次LAI-AP注射的情况。方法:18岁及以上的患者如果在住院期间接受了LAI-AP,并同意监测他们90天的随访,则符合纳入的条件。主要结果确定了在精神病住院期间出院后首次就诊时接受相同LAI-AP治疗的患者的百分比。次要结果比较了LAI-AP随访计划、口腔重叠和早期精神病学再住院率的适当记录。结果:纳入51例患者。29例患者(56.9%)出院后在门诊随访,并按计划接受下一次计划的LAI-AP治疗。22名患者(43.1%)出院后未接受LAI-AP注射,其中15名患者未参加最初的随访预约。39例患者(76.5%)新开始接受LAI-AP治疗,其中19例接受下一次随访注射。讨论:超过40%接受LAI-AP住院治疗的患者,尽管有适当的出院计划,但在门诊没有随访。更有可能接受后续LAI-AP治疗的患者年龄较大,住院期间接受维持注射,并有预定的随访预约。在患者接受LAI-AP治疗前,应考虑多种因素,包括门诊依从性、可及性、门诊继续治疗的可行性和护理计划的过渡。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.90
自引率
0.00%
发文量
0
期刊最新文献
Pharmacists expand access to contingency management in patients with substance use disorders. Treatment of disruptive mood dysregulation disorder with autism spectrum disorder and attention-deficit/hyperactivity disorder. Protracted escitalopram discontinuation syndrome and serotonin toxicity associated with CYP2C19 poor metabolism: A case report. Inpatient prescribing trends and differences in drug acquisition costs of long-acting injectable subcutaneous risperidone versus paliperidone palmitate: A single-center medication use evaluation. Lithium toxicity following a change from semaglutide to tirzepatide for weight loss management.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1